FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140104756> ?p ?o ?g. }

• W2140104756 endingPage "1767" @default.
• W2140104756 startingPage "1762" @default.
• W2140104756 abstract "Gemcitabine (difluorodeoxycytidine) is active as a single agent in Hodgkin's disease and has been used successfully in combination with cisplatin to treat a variety of solid tumors.We evaluated the combination of gemcitabine/dexamethasone/cisplatin (GDP) as salvage chemotherapy in 23 patients with relapsed or refractory Hodgkin's disease (median age 36 years, range 19-57). Treatment consisted of gemcitabine 1000 mg/m(2) intravenously on days 1 and 8, dexamethasone 40 mg orally days 1-4 and cisplatin 75 mg/m(2) on day 1, every 21 days as an outpatient. Response was assessed following two cycles of treatment.There were four complete responses and 12 partial responses for a response rate of 69.5% (95% confidence interval 52% to 87%); the remaining seven patients had stable disease and no patient progressed on treatment. All patients had successful stem cell mobilization and underwent transplantation with a median 10.6 x 10(6) CD34+ cells/kg. Hematological toxicity from GDP was mild (grade 3 neutropenia 8.6%, grade 3 thrombocytopenia 13%).In summary, GDP is an active regimen for patients with relapsed or refractory Hodgkin's disease. The response rate is similar to the rates of other current salvage regimens, it can be given to outpatients with tolerable toxicity and it does not inhibit the mobilization of autologous stem cells." @default.
• W2140104756 created "2016-06-24" @default.
• W2140104756 creator A5002916492 @default.
• W2140104756 creator A5011173909 @default.
• W2140104756 creator A5027298568 @default.
• W2140104756 creator A5031334254 @default.
• W2140104756 creator A5032098740 @default.
• W2140104756 creator A5037155506 @default.
• W2140104756 creator A5056706511 @default.
• W2140104756 creator A5061856914 @default.
• W2140104756 creator A5065613714 @default.
• W2140104756 creator A5073964632 @default.
• W2140104756 creator A5086588458 @default.
• W2140104756 creator A5091222951 @default.
• W2140104756 date "2003-12-01" @default.
• W2140104756 modified "2023-09-30" @default.
• W2140104756 title "Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group" @default.
• W2140104756 cites W1749229087 @default.
• W2140104756 cites W1810011631 @default.
• W2140104756 cites W1822166136 @default.
• W2140104756 cites W1901841160 @default.
• W2140104756 cites W1914654455 @default.
• W2140104756 cites W1940892707 @default.
• W2140104756 cites W1944058895 @default.
• W2140104756 cites W1984254136 @default.
• W2140104756 cites W1987792231 @default.
• W2140104756 cites W1998484959 @default.
• W2140104756 cites W2035567465 @default.
• W2140104756 cites W2066068982 @default.
• W2140104756 cites W2076334524 @default.
• W2140104756 cites W2076668534 @default.
• W2140104756 cites W2101562875 @default.
• W2140104756 cites W2103699612 @default.
• W2140104756 cites W2122654415 @default.
• W2140104756 cites W2136945691 @default.
• W2140104756 cites W2141082026 @default.
• W2140104756 cites W2157717016 @default.
• W2140104756 cites W2159746531 @default.
• W2140104756 cites W2163991732 @default.
• W2140104756 cites W2165308914 @default.
• W2140104756 cites W2166399931 @default.
• W2140104756 cites W2227689191 @default.
• W2140104756 cites W2243629813 @default.
• W2140104756 cites W4249283733 @default.
• W2140104756 cites W4297819854 @default.
• W2140104756 cites W4302388935 @default.
• W2140104756 doi "https://doi.org/10.1093/annonc/mdg496" @default.
• W2140104756 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14630682" @default.
• W2140104756 hasPublicationYear "2003" @default.
• W2140104756 type Work @default.
• W2140104756 sameAs 2140104756 @default.
• W2140104756 citedByCount "141" @default.
• W2140104756 countsByYear W21401047562012 @default.
• W2140104756 countsByYear W21401047562013 @default.
• W2140104756 countsByYear W21401047562014 @default.
• W2140104756 countsByYear W21401047562015 @default.
• W2140104756 countsByYear W21401047562016 @default.
• W2140104756 countsByYear W21401047562017 @default.
• W2140104756 countsByYear W21401047562018 @default.
• W2140104756 countsByYear W21401047562019 @default.
• W2140104756 countsByYear W21401047562020 @default.
• W2140104756 countsByYear W21401047562021 @default.
• W2140104756 countsByYear W21401047562022 @default.
• W2140104756 countsByYear W21401047562023 @default.
• W2140104756 crossrefType "journal-article" @default.
• W2140104756 hasAuthorship W2140104756A5002916492 @default.
• W2140104756 hasAuthorship W2140104756A5011173909 @default.
• W2140104756 hasAuthorship W2140104756A5027298568 @default.
• W2140104756 hasAuthorship W2140104756A5031334254 @default.
• W2140104756 hasAuthorship W2140104756A5032098740 @default.
• W2140104756 hasAuthorship W2140104756A5037155506 @default.
• W2140104756 hasAuthorship W2140104756A5056706511 @default.
• W2140104756 hasAuthorship W2140104756A5061856914 @default.
• W2140104756 hasAuthorship W2140104756A5065613714 @default.
• W2140104756 hasAuthorship W2140104756A5073964632 @default.
• W2140104756 hasAuthorship W2140104756A5086588458 @default.
• W2140104756 hasAuthorship W2140104756A5091222951 @default.
• W2140104756 hasBestOaLocation W21401047561 @default.
• W2140104756 hasConcept C126322002 @default.
• W2140104756 hasConcept C141071460 @default.
• W2140104756 hasConcept C143998085 @default.
• W2140104756 hasConcept C2776694085 @default.
• W2140104756 hasConcept C2777063308 @default.
• W2140104756 hasConcept C2778336483 @default.
• W2140104756 hasConcept C2778822529 @default.
• W2140104756 hasConcept C2780258809 @default.
• W2140104756 hasConcept C2780401358 @default.
• W2140104756 hasConcept C2780775027 @default.
• W2140104756 hasConcept C2781413609 @default.
• W2140104756 hasConcept C2911091166 @default.
• W2140104756 hasConcept C31760486 @default.
• W2140104756 hasConcept C71924100 @default.
• W2140104756 hasConcept C90924648 @default.
• W2140104756 hasConceptScore W2140104756C126322002 @default.
• W2140104756 hasConceptScore W2140104756C141071460 @default.
• W2140104756 hasConceptScore W2140104756C143998085 @default.
• W2140104756 hasConceptScore W2140104756C2776694085 @default.
• W2140104756 hasConceptScore W2140104756C2777063308 @default.

• next